Literature DB >> 1623913

Inhibition of cyclooxygenase attenuates baroreceptor function and increases the pressor response to norepinephrine in man.

B Weisser1, G Kayser, S Wagner, B O Göbel, H Vetter, R Düsing.   

Abstract

The possible influence of prostaglandins on baroreceptor function in man has been investigated. Baroreceptor reflex was activated by intravenous infusion of norepinephrine and the pressor response was measured, both before and after administration of indomethacin. Resting blood pressure remained unchanged after indomethacin while resting heart rate was significantly decreased as compared to placebo and the norepinephrine-induced rise in mean arterial blood pressure was significantly more pronounced. The baroreceptor-mediated decrease in heart rate tended to be smaller. Baroreceptor sensitivity (delta heart rate/delta blood pressure) was significantly reduced by indomethacin to about half of the control value. In addition to attenuation of sensitivity, the findings represent resetting of the baroreceptor setpoint and a more pronounced pressor response to norepinephrine after cyclooxygenase inhibition. Thus, eicosanoids originating via the cyclooxygenase pathway of arachidonate metabolism may modulate the vascular response to adrenergic stimulation and may participate in the regulation of baroreceptor reflex setpoint and sensitivity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1623913     DOI: 10.1007/bf00265937

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

Review 1.  Systemic arterial baroreceptor reflexes.

Authors:  H R Kirchheim
Journal:  Physiol Rev       Date:  1976-01       Impact factor: 37.312

2.  Arterial baroreceptor control of peripheral vascular resistance in experimental heart failure.

Authors:  J R Wilson; V Lanoce; M J Frey; N Ferraro
Journal:  Am Heart J       Date:  1990-05       Impact factor: 4.749

3.  Diminished baroreflex sensitivity in high blood pressure.

Authors:  J D Bristow; A J Honour; G W Pickering; P Sleight; H S Smyth
Journal:  Circulation       Date:  1969-01       Impact factor: 29.690

Review 4.  The clinical significance of inhibition of renal prostaglandin synthesis.

Authors:  C Patrono; M J Dunn
Journal:  Kidney Int       Date:  1987-07       Impact factor: 10.612

5.  Baroreflex setting and sensitivity in normal subjects: effects of pharmacologic inhibition of the angiotensin I converting enzyme.

Authors:  R Düsing; G Kayser; S Wagner; H Scherf; K Glänzer; H G Predel; H J Kramer
Journal:  Am J Cardiol       Date:  1987-04-24       Impact factor: 2.778

6.  Prostaglandins in carotid sinus enhance baroreflex in rabbits.

Authors:  T S McDowell; T S Axtelle; M W Chapleau; F M Abboud
Journal:  Am J Physiol       Date:  1989-08

7.  Arachidonic acid metabolites, hypertension and arteriosclerosis.

Authors:  P C Weber; W Siess; B Scherer; E Held; H Witzgall; R Lorenz
Journal:  Klin Wochenschr       Date:  1982-05-17

8.  Some direct and reflex cardiovascular actions of prostacyclin (PGI2) and prostaglandin E2 in anaesthetized dogs.

Authors:  D J Chapple; G J Dusting; R Hughes; J R Vane
Journal:  Br J Pharmacol       Date:  1980-03       Impact factor: 8.739

9.  Inhibition by prostaglandins of adrenergic transmission in the left ventricular myocardium of anesthetized dogs.

Authors:  S M Lanier; K U Malik
Journal:  J Cardiovasc Pharmacol       Date:  1985 Jul-Aug       Impact factor: 3.105

10.  Prostacyclin production by cultured endothelial cell monolayers exposed to step increases in shear stress.

Authors:  E F Grabowski; E A Jaffe; B B Weksler
Journal:  J Lab Clin Med       Date:  1985-01
View more
  1 in total

1.  Aspirin augments carotid-cardiac baroreflex sensitivity during muscle mechanoreflex and metaboreflex activation in humans.

Authors:  Rachel C Drew; Matthew D Muller; Cheryl A Blaha; Jessica L Mast; Michael D Herr; Sean D Stocker; Lawrence I Sinoway
Journal:  J Appl Physiol (1985)       Date:  2013-08-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.